- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06238609
Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome
Post-intensive care syndrome (PICS) encompasses persistent physical, cognitive, and psychiatric symptoms following ICU discharge, commonly triggered by serious conditions such as respiratory failure, sepsis, and mechanical ventilation. PICS prevalence is reported to be as high as 84% up to 12 months in patients with at least 2 days spent in the ICU or with mechanical ventilatory support. As a consequence, many patients do not return to they former level of function for weeks, months and even years.
Muscular affection manifested by muscle weakness is particularly seen and is provoked by a combination of damage to the nerves or directly the muscles fibers. This affection is referred to as CU-Acquired Weakness (ICUAW). One third of the time, lower extremities are affected, often due to prolonged immobilization or sedation. Evidence suggests that early mobilization reduces the incidence of ICUAW at discharge and improves the number of patients able of stand. However achieving this early intervention is not always feasible due to time or personnel constraints.
The purpose of the study is to examine the effectiveness of lower extremity neuromodulation for prevention of muscle deconditioning in patients admitted to the ICU.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of the study is to examine feasibility and acceptability of lower extremity neuromodulation in patients at risk of ICUAW. This is a proof Randomized controlled trial (RCT) study for prevention. Eligible participants will be recruited from Baylor St Luke's Medical Center (Houston, Texas).
Participants will be randomized to intervention group (IG) or control group (CG). The entire cohort will receive daily neuromodulation in the lower extremity (Gastrocnemius muscle, Achilles tendon) up to 1 hour. The therapy will be provided with a neuromodulation device (Tennant Biomodulator PRO®, AVAZZIA, Inc.) that works on high voltage alternative pulsed current. The device will be functional for the IG and non-functional for the CG.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Maria Noun, BS
- Phone Number: 713-798-7538
- Email: maria.noun@bcm.edu
Study Contact Backup
- Name: Bijan Najafi, PhD
- Phone Number: 713-798-7538
- Email: bijan.najafi@bcm.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor College of Medicine
-
Contact:
- Maria Noun, BS
- Phone Number: 713-798-7538
- Email: maria.noun@bcm.edu
-
Contact:
- Bijan Najafi, PhD
- Phone Number: 713-798-7536
- Email: bijan.najafi@bcm.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient older than 18 years old admitted to the ICU within 2 days.
- Patient can be intubated with ventilatory assistance or not.
Exclusion Criteria:
- Less than 48 hours of ICU stay.
- Major foot problems such as active lower extremity wounds, major foot deformity (e.g., Charcot Foot), and/or previous major amputations.
- Demand-type cardiac pacemaker, implanted defibrillator, or other implanted electronic devices.
- Any conditions that may interfere with outcomes or increase the risk of the use neuromodulation therapy based on the judgement of clinicians.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention Group
Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
|
Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
|
Sham Comparator: Control group
Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
|
Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrocnemius muscle endurance at 4 weeks
Time Frame: Up to 4 weeks
|
Gastrocnemius muscle endurance will be measured in response to 5 minute neuromodulation recorded by surface electromyography (Delsys Trigno).
|
Up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrocnemius muscle thickness at 4 weeks
Time Frame: up to 4 weeks
|
Thickness of medial gastrocnemius muscle will be measured using portable muscle ultrasound (VscanAir).
|
up to 4 weeks
|
Plantar Saturation of oxygen at 4 weeks
Time Frame: up to 4 weeks
|
Plantar saturation of oxygen will be obtained before and after neuromodulation for 1 hour.
A non-invasive near-infrared spectroscopy camera (Snapshot, Kent imaging) will be used to obtain Saturation of Oxygen in response to neuromodulation.
|
up to 4 weeks
|
Ankle strength at 4 weeks
Time Frame: up to 4 weeks
|
Maximum Voluntary Contraction will be assed using a dynamometer during isometric plantar flexion for 5 seconds.
|
up to 4 weeks
|
Sural nerve conduction at 4 weeks
Time Frame: up to 4 weeks.
|
Sural nerve conduction will be assessed using the DPN check device (Neurometrix Inc).
|
up to 4 weeks.
|
Sural nerve amplitude at 4 weeks
Time Frame: up to 4 weeks.
|
Sural nerve amplitude will be assessed using the DPN check device (Neurometrix Inc).
|
up to 4 weeks.
|
Deep Vein Thrombosis events at 4 weeks
Time Frame: up to 4 weeks.
|
Deep Vein Thrombosis events will be obtained from the patient electronic medical records' doppler ultrasound technician report.
|
up to 4 weeks.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety level 4 weeks after hospital discharge
Time Frame: 1 month after study termination (up to 8 weeks).
|
Anxiety levels will be measured using the Beck anxiety inventory validated questionnaire.
The minimum score is 0, meaning low anxiety, and the maximum score is 63 , meaning potential concerning levels of anxiety.
|
1 month after study termination (up to 8 weeks).
|
Independence activities of daily living (IADL) 4 weeks after hospital discharge
Time Frame: 1 month after study termination (up to 8 weeks).
|
Independence activities of daily living will be measured using Katz Index Scale .
The minimum score is 0, meaning patient independent, and the maximum score is 6, meaning patient very dependent.
|
1 month after study termination (up to 8 weeks).
|
Instrumental Activities of daily living (IADL) 4 weeks after hospital discharge
Time Frame: 1 month after study termination (up to 8 weeks).
|
Independence in Instrumental activities of daily living will be measured Lawton Brody Scale .
The minimum score is 0, meaning low function-dependent, and the maximum score is 8, meaning high function independent.
|
1 month after study termination (up to 8 weeks).
|
Individuals mobility and participation in various life spaces or environments
Time Frame: 1 month after study termination (up to 8 weeks).
|
Individuals functional mobility and extent of community engagement will be measured with the UAB life space questionnaire.
The minimum score is 0, totally bed-bound, and the maximum score is 120, meaning traveling everyday out of town without assistance.
|
1 month after study termination (up to 8 weeks).
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-52968
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Weakness
-
St. Luke's-Roosevelt Hospital CenterCompletedFall Risk | Quadriceps Muscle Weakness | Adductor Muscle WeaknessUnited States
-
University of Central ArkansasCompletedPelvic Floor Muscle WeaknessUnited States
-
Association Pro-arteActive, not recruitingWeakness, Muscle | AmyotrophiaFrance
-
Ludwig Boltzmann Institute of Electrical Stimulation...Medical University of Vienna; European Union; Comenius University; Ministry of...CompletedMuscle Weakness Condition | Therapy EffectAustria, Slovakia
-
Rutgers, The State University of New JerseyRecruitingPhysical Disability | Muscle Atrophy or Weakness | Muscle Loss | Physical Inactivity | Delirium in Old Age | Hospital Acquired Condition | Weakness, MuscleUnited States
-
University of MilanCompleted
-
University of Central FloridaCompletedMuscle Weakness | Muscle Atrophy | Muscle Loss | Weakness, Muscle | Injury, KneeUnited States
-
University of Texas Southwestern Medical CenterTerminatedMuscle Cramp | Statin Adverse Reaction | Weakness, Muscle | AcheUnited States
-
Damanhour UniversityCompletedNeuromuscular Electrical Stimulation | ICU Acquired Muscle WeaknessEgypt
-
Riphah International UniversityCompletedMuscle Weakness ConditionPakistan
Clinical Trials on Intervention Group
-
Muğla Sıtkı Koçman UniversityNot yet recruiting
-
University of LiegeCentre Hospitalier Universitaire de Liege; Bial Foundation; FNRS (Télévie); Fondation...RecruitingPain | Cancer | Fatigue | Cognitive Impairment | Sleep Disturbance | Distress, EmotionalBelgium
-
Hospital de Clinicas de Porto AlegreUnknown
-
University of California, San FranciscoNational Cancer Institute (NCI); Cancer Prevention Institute of CaliforniaCompletedHereditary Breast and Ovarian Cancer Syndrome
-
University of Sao PauloCompletedAnxiety | Self Esteem
-
Haute Ecole de Santé VaudCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSwitzerland
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
Azienda Ospedaliero-Universitaria CareggiRecruiting
-
Vitalija StonkuvienėRecruitingFrailty SyndromeLithuania